CRNX vs. IONS, AVDL, BCYC, AGLE, BMRN, VTRS, UTHR, RDY, SRPT, and CTLT
Should you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Ionis Pharmaceuticals (IONS), Avadel Pharmaceuticals (AVDL), Bicycle Therapeutics (BCYC), Aeglea BioTherapeutics (AGLE), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), and Catalent (CTLT). These companies are all part of the "pharmaceutical preparations" industry.
Crinetics Pharmaceuticals (NASDAQ:CRNX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.
In the previous week, Ionis Pharmaceuticals had 2 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 9 mentions for Ionis Pharmaceuticals and 7 mentions for Crinetics Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.93 beat Crinetics Pharmaceuticals' score of 0.54 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.
Ionis Pharmaceuticals received 536 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 67.30% of users gave Crinetics Pharmaceuticals an outperform vote while only 60.16% of users gave Ionis Pharmaceuticals an outperform vote.
Ionis Pharmaceuticals has a net margin of -49.49% compared to Crinetics Pharmaceuticals' net margin of -4,223.27%. Crinetics Pharmaceuticals' return on equity of -42.50% beat Ionis Pharmaceuticals' return on equity.
98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 6.0% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Crinetics Pharmaceuticals has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Crinetics Pharmaceuticals has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.
Crinetics Pharmaceuticals presently has a consensus price target of $60.92, indicating a potential upside of 37.17%. Ionis Pharmaceuticals has a consensus price target of $59.54, indicating a potential upside of 58.47%. Given Ionis Pharmaceuticals' higher probable upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.
Summary
Crinetics Pharmaceuticals beats Ionis Pharmaceuticals on 10 of the 19 factors compared between the two stocks.
Get Crinetics Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Crinetics Pharmaceuticals Competitors List
Related Companies and Tools
